CA3011819A1 - Compositions and methods for inhibiting factor d - Google Patents

Compositions and methods for inhibiting factor d Download PDF

Info

Publication number
CA3011819A1
CA3011819A1 CA3011819A CA3011819A CA3011819A1 CA 3011819 A1 CA3011819 A1 CA 3011819A1 CA 3011819 A CA3011819 A CA 3011819A CA 3011819 A CA3011819 A CA 3011819A CA 3011819 A1 CA3011819 A1 CA 3011819A1
Authority
CA
Canada
Prior art keywords
aptamer
factor
complement factor
seq
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3011819A
Other languages
English (en)
French (fr)
Inventor
Carl ERICKSON
Christopher P. Rusconi
Kevin G. Mclure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
396419 BC Ltd
Original Assignee
Vitrisa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitrisa Therapeutics Inc filed Critical Vitrisa Therapeutics Inc
Publication of CA3011819A1 publication Critical patent/CA3011819A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
CA3011819A 2016-01-20 2017-01-20 Compositions and methods for inhibiting factor d Pending CA3011819A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662281092P 2016-01-20 2016-01-20
US62/281,092 2016-01-20
US201662297095P 2016-02-18 2016-02-18
US62/297,095 2016-02-18
PCT/US2017/014458 WO2017127761A1 (en) 2016-01-20 2017-01-20 Compositions and methods for inhibiting factor d

Publications (1)

Publication Number Publication Date
CA3011819A1 true CA3011819A1 (en) 2017-07-27

Family

ID=59362699

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3011819A Pending CA3011819A1 (en) 2016-01-20 2017-01-20 Compositions and methods for inhibiting factor d

Country Status (8)

Country Link
US (4) US10174325B2 (https=)
EP (1) EP3405577B8 (https=)
JP (3) JP2019506159A (https=)
CN (1) CN108934169A (https=)
AU (3) AU2017210042B2 (https=)
CA (1) CA3011819A1 (https=)
GB (1) GB2553252B (https=)
WO (1) WO2017127761A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20200182T1 (hr) 2014-02-25 2020-05-01 Achillion Pharmaceuticals, Inc. Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) * 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2018136831A1 (en) * 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Pseudoknot compositions and methods for inhibiting factor d
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2019022986A1 (en) * 2017-07-24 2019-01-31 Vitrisa Therapeutics, Inc. NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
WO2019210194A1 (en) * 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
KR20210104071A (ko) 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
WO2020146731A1 (en) * 2019-01-11 2020-07-16 Drive Therapeutics Llc Compositions and methods for inhibiting vascular endothelial growth factor
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
EP4048318A4 (en) * 2019-10-23 2023-11-22 Gemini Therapeutics Sub, Inc. METHOD FOR TREATING PATIENTS WITH CFH MUTATIONS USING RECOMBINANT CFH PROTEINS
CN114686481B (zh) * 2020-12-31 2023-08-15 北京键凯科技股份有限公司 一种抑制cfd表达的干扰rna及其制备方法和应用
WO2025080823A1 (en) * 2023-10-11 2025-04-17 Regeneron Pharmaceuticals, Inc. Treatment of macular degeneration with complement factor d (cfd) inhibitors

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US6653340B1 (en) 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
AU756490B2 (en) 1997-08-26 2003-01-16 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway
WO1999027133A1 (en) 1997-11-26 1999-06-03 Medical Research Council Improved selex procedure and an anti-cd4 aptamer
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
AU2001249410A1 (en) 2000-03-23 2001-10-03 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
EP1594541A4 (en) 2003-02-21 2007-03-28 Rikshospitalet Radiumhospitale METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
AU2006223108A1 (en) 2005-03-11 2006-09-21 Potentia Pharmaceuticals, Inc. Compositions comprising modulators of G-protein-coupled receptor for treatment of macular degeneration
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
CN101346473A (zh) 2005-12-22 2009-01-14 爱尔康研究有限公司 用于在具有补体因子h的风险变体的患者中预防和治疗年龄相关性黄斑变性的c3-转化酶抑制剂
ATE466081T1 (de) 2005-12-22 2010-05-15 Opko Ophthalmics Llc Zusammensetzungen und verfahren zur regulierung eines komplementsystems
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
KR101584468B1 (ko) 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
US8790924B2 (en) 2006-10-19 2014-07-29 Duke University Reversible platelet inhibition
CN106188303A (zh) 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
US20080269318A1 (en) * 2007-04-30 2008-10-30 Carmelo Romano Treatment of age-related macular degeneration using inhibitors of complement factor d
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
US20090092980A1 (en) 2007-07-20 2009-04-09 Christoph Arenz miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
GB0718737D0 (en) 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
UY31520A1 (es) 2007-12-11 2009-08-03 Proteinas de union a antigenos
EP2254411A4 (en) 2008-02-19 2012-06-13 Univ Pennsylvania COMPLEMENT INHIBITORS AS A THERAPEUTIC FOR THE TREATMENT OF CANCER
WO2009108931A2 (en) 2008-02-28 2009-09-03 Case Western Reserve University Method of treating cancer
US8435512B2 (en) 2008-03-03 2013-05-07 Novelmed Therapeutics, Inc. Anti-properdin antibodies
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
EP2278987A4 (en) 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
EP2159286A1 (en) 2008-09-01 2010-03-03 Consiglio Nazionale Delle Ricerche Method for obtaining oligonucleotide aptamers and uses thereof
US20110160636A1 (en) 2008-09-10 2011-06-30 Rekha Bansal Device and method for inhibiting complement activation
GB0904427D0 (en) * 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
US9382544B2 (en) 2009-05-15 2016-07-05 Nec Solution Innovators, Ltd. Aptamer that recognizes peptide
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
US9278108B2 (en) 2009-07-16 2016-03-08 Nec Solution Innovators, Ltd. HMGB1 binding nucleic acid molecule and applications thereof
US20120190578A1 (en) 2009-08-06 2012-07-26 Washington University Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
DK2635704T3 (en) 2010-11-01 2017-06-19 Hoffmann La Roche Predicting progression to advanced age-related macular degeneration using a polygenic score
EP2661433B1 (en) 2011-01-04 2017-08-16 Novartis AG Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
US10966945B2 (en) 2011-08-01 2021-04-06 Aurin Biotech Inc. Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex
WO2013047844A1 (ja) 2011-09-28 2013-04-04 株式会社リボミック Ｎｇｆに対するアプタマー及びその用途
EP2798085B1 (en) 2011-12-30 2018-01-24 Quest Diagnostics Investments Incorporated Aptamers and diagnostic methods for detecting the egf receptor
MX374090B (es) 2013-03-14 2025-03-05 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
US20150104445A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
HRP20200182T1 (hr) 2014-02-25 2020-05-01 Achillion Pharmaceuticals, Inc. Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja
EP3137503A1 (en) * 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
TWI623617B (zh) 2014-08-29 2018-05-11 國立清華大學 對卵巢癌具有專一性之適合體及其應用
US20180356408A1 (en) 2015-11-19 2018-12-13 Base Pair Biotechnologies, Inc. Methods and materials for sensitive detection of target molecules
WO2017127762A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Methods for improved aptamer selection
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2018136831A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Pseudoknot compositions and methods for inhibiting factor d
WO2019022986A1 (en) 2017-07-24 2019-01-31 Vitrisa Therapeutics, Inc. NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR

Also Published As

Publication number Publication date
EP3405577A1 (en) 2018-11-28
EP3405577B1 (en) 2022-12-14
US20200392502A1 (en) 2020-12-17
GB201718801D0 (en) 2017-12-27
JP2022078283A (ja) 2022-05-24
GB2553252A8 (en) 2018-03-14
AU2017210042B2 (en) 2021-01-21
US20250197868A1 (en) 2025-06-19
WO2017127761A1 (en) 2017-07-27
AU2023202548A1 (en) 2023-06-01
AU2021202392A1 (en) 2021-05-20
US20180051287A1 (en) 2018-02-22
US11274307B2 (en) 2022-03-15
EP3405577A4 (en) 2019-09-11
US20190161755A1 (en) 2019-05-30
JP2024029136A (ja) 2024-03-05
HK1251610A1 (zh) 2019-02-01
CN108934169A (zh) 2018-12-04
AU2017210042A1 (en) 2018-07-26
EP3405577B8 (en) 2023-02-15
GB2553252B (en) 2019-07-31
GB2553252A (en) 2018-02-28
US10174325B2 (en) 2019-01-08
AU2021202392B2 (en) 2023-02-02
JP2019506159A (ja) 2019-03-07

Similar Documents

Publication Publication Date Title
AU2021202392B2 (en) Compositions and methods for inhibiting Factor D
RU2477137C2 (ru) Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
JP6587934B2 (ja) Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
JP2012528597A (ja) 血小板グリコプロテインｖｉの核酸調節因子
US11466276B2 (en) Stem-loop compositions and methods for inhibiting factor D
US12534734B2 (en) Stem-loop compositions and methods for inhibiting interleukin-8
WO2018136831A1 (en) Pseudoknot compositions and methods for inhibiting factor d
WO2019022986A1 (en) NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR
WO2020247850A1 (en) Compositions and methods for inhibiting angiopoietin-2
US12540330B2 (en) Stem-loop compositions and methods for inhibiting vascular endothelial growth factor
AU2022202115A1 (en) Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
Bege et al. Avacincaptad pegol, the second approved aptamer medicine–A mini review
WO2020146731A1 (en) Compositions and methods for inhibiting vascular endothelial growth factor
AU2020201145A1 (en) Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220118

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241114

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250117

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250314

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250319

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250412

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250412

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20251223

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R125 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMMON REPRESENTATIVE APPOINTED

Effective date: 20260107

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260107

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260116

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260116

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260409